Pharmaceuticals News and Research

RSS

New synchrotron-based imaging technique offers more detailed chemical images

With intensity a million times brighter than sunlight, a new synchrotron-based imaging technique offers high-resolution pictures of the molecular composition of tissues with unprecedented speed and quality. Carol Hirschmugl, a physicist at the University of Wisconsin-Milwaukee (UWM), led a team of researchers from UWM, the University of Illinois at Urbana-Champaign and University of Illinois at Chicago (UIC) to demonstrate these new capabilities.

21 Mar 2011

Ontario announces passage of regulations that fully enable remote pharmacy dispensing

The Government of Ontario today announced passage of regulations that fully enable remote pharmacy dispensing in all areas of the province. Further to the provisions of Bill 179, passed in December 2009, these regulations provide the framework for how remote dispensing will occur in Ontario, and mark a historic moment in health care delivery in Canada.

19 Mar 2011

BioMarin announces preliminary results from ADAPT in patients suffering from PKU

BioMarin Pharmaceutical Inc. announced today preliminary results from ADAPT (A Diversified Approach for PKU Treatment) in an abstract (Abstract #91, Mental Health Screening in Phenylketoniuria Clinic) presented by Barbara Burton, MD at the 2011 annual American College of Medical Genetics conference in Vancouver, Canada.

19 Mar 2011

Quark Pharmaceuticals receives results from Phase 2 trial of PF-04523655 in patients with DME

Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced that it has received results from a prospective randomized Phase 2 trial, the DEGAS study.

19 Mar 2011

EMA CHMP adopts positive opinion for Teva's NOMAC-E2 contraceptive pill

Teva Pharmaceutical Industries Ltd. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for NOMAC-E2, an investigational contraceptive pill combining 1.5 mg of 17-beta-estradiol with 2.5 mg of nomegestrol acetate in a 24/4 monophasic regimen.

18 Mar 2011

Cortex reports net loss of $0.01 per share for quarter ended December 31, 2010

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of $984,000, or $0.01 per share for the quarter ended December 31, 2010 compared with a net loss of $1,599,000, or $0.02 per share for the corresponding prior year period.

18 Mar 2011

MHA hosts two-day Long Term Care Business Summit at ARIA

Managed Health Care Associates, Inc., a leading health care service company focused on alternate site health care providers, is hosting its 8th Annual MHA Business Summit for Long Term Care Pharmacies and other Long Term Care stakeholders on March 17th-18th at ARIA at CityCenter in Las Vegas, Nevada.

18 Mar 2011

SCRIP to launch new pharma Lifecycle Management microsite

SCRIP Intelligence - the leading news, analysis and data service for the global pharmaceutical industry - is launching 'Lessons in Lifecycle Management' opening up an evolving roadmap for a vital, and often misunderstood, skill in the industry that aims to maximize a pharmaceutical product's commercial value.

18 Mar 2011

Alnylam to defend against Tekmira complaint

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, is reporting the filing of a complaint by Tekmira Pharmaceuticals Corporation in the Business Litigation Session (BLS) of the Massachusetts Superior Court. The complaint alleges misappropriation and misuse of information, amongst other allegations.

18 Mar 2011

MeadWestvaco's Mebane packaging plant earns FSC Chain of Custody certification

MeadWestvaco Corp. announced today that its Mebane, N.C. packaging plant received Forest Stewardship Council Chain of Custody certification in February 2011.

18 Mar 2011

Covidien provides update on its operations in Japan

Covidien, a leading global supplier of healthcare products, today provided an update on its operations in Japan.

18 Mar 2011

Anacor Pharma, MMV enter agreement to develop AN3661 for malaria treatment

Anacor Pharmaceuticals announced today that it has entered into a development agreement with Medicines for Malaria Venture to develop Anacor's compound AN3661 for the treatment of malaria.

18 Mar 2011

Roundup: Cuts in Calif. programs; Ga. seeks federal MLR waiver; N.J. lawmakers try to restore some health funding

State lawmakers Wednesday approved billions of dollars in cuts to welfare, medical programs for the poor and in-home care for the elderly and frail, among other services, moving forward key pieces of Gov. Jerry Brown's budget reduction package.

18 Mar 2011

New drug can aid in smoking reduction therapy

Researchers working in a research project within the Academy of Finland's Research Programme on Substance Use and Addictions have been developing a targeted drug that could aid in smoking reduction therapy. The new drug slows down the metabolism of nicotine, which would help smokers to cut down their smoking.

18 Mar 2011

Positron to introduce its radiopharmaceutical system at American College of Cardiology

Positron Corporation, a leading molecular imaging company specializing in the field of nuclear cardiology, announced the introduction of its automated radiopharmaceutical system, under the name PosiRx, at two upcoming industry conferences.

18 Mar 2011

China Botanic first quarter net sales increase 32.1% to $22.6 million

China Botanic Pharmaceutical Inc., a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, today announced financial results for the three months ended January 31, 2011, and reaffirmed guidance for its full fiscal year ending October 31, 2011.

17 Mar 2011

CytRx commences INNO-206 Phase 1b trial in advanced solid tumors

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it has initiated an open-label Phase 1b safety and dose escalation clinical trial with INNO-206 at the Sarcoma Oncology Center in Santa Monica, California. The clinical trial will include up to 24 patients with advanced solid tumors who have failed standard therapies.

17 Mar 2011

Astellas to acquire all Maxygen's equity interests in Perseid for $76.0 million

Maxygen, Inc. today announced that Astellas Pharma Inc. has exercised its option to purchase all of Maxygen's equity interests in Perseid Therapeutics LLC at the current exercise price of $76.0 million.

17 Mar 2011

pIMAGO nanopolymer can test cancer drug efficacy against biochemical processes

A Purdue University scientist's nanopolymer would make it easier and cheaper for drug developers to test the effectiveness of a widely used class of cancer inhibitors.

17 Mar 2011

Inovio signs agreement with OncoSec to sell non-DNA cancer vaccine technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has signed an agreement with OncoSec Medical Inc. providing for the sale to OncoSec of certain non-DNA vaccine technology and intellectual property relating to electroporation technology useful for electrochemical and cytokine based immune therapies for treating solid tumors.

17 Mar 2011